Immutep tries again
After Tacti-003’s controlled cohorts fail, Immutep plays up single-arm data in PD-L1 non-expressers.
Scancell faces its big decision
Data in the coming months will inform which immunotherapy the UK company takes into pivotal development.
Where next for TIGIT?
The implosion of Skyscraper-06 has a direct impact on at least two other TIGIT players.
FDA green and red lights: June 2024
Merck and Daiichi’s first ADC attempt is knocked back, while Geron gets its inaugural approval.
Immutep stumbles on into phase 3
Predictably Tacti-003 fails, but funding is secured – from investors, not a partner.
Merck’s big ADC deal takes a blow
A complete response letter for Merck & Co and Daiichi’s patritumab deruxtecan might not be fatal, but it’s certainly embarrassing.
Bristol overtakes Amgen in colorectal
Meanwhile, Bristol’s other competition in this disease looks set to come from China.
Merck seeks the next Keytruda
The group’s Kelun-partnered TROP2 ADC looks like a bargain, but Merck’s pipeline has big shoes to fill.
Toxicity hits BioNTech’s MediLink tie-up
A mysterious ASCO poster, patient deaths and now clinical hold; where next for BioNTech’s ADC deal?
